Recent YSCC Discoveries

Yale researchers are improving the treatment of childhood anxiety by investigating all aspects of the disorder, down to the molecular level.

Bernard “Bernie” Bober’s $1M gift to Yale School of Medicine fuels cancer research, inspired by his and his family’s own cancer experiences.

Dr. Chupp asks Dr. Hanania whether he tapers inhalers in patients on biologics, noting the SHAMAL results were dramatic but ran under a year, that most remission data are observational, and that controlled studies suggest perhaps 20% reduce inhaled steroids versus controls.

Dr. Chupp asks Dr. Hanania whether anti-TSLP availability has shifted him toward using an anti-alarmin first, given trial data showing efficacy across the spectrum without requiring a biomarker, and whether he considers combination therapy or overlapping agents when switching.

Dr. Chupp reframes the discussion around the patient. The goal is no longer stopping exacerbations; it is remission.

Research core facilities offer access to expertise and advanced equipment—and they empower scientists to focus on the big-picture questions in their fields.

Erica Herzog, MD, PhD, has been appointed section chief of Pulmonary, Critical Care and Sleep Medicine in the Yale Department of Internal Medicine, effective October 1, 2026.

The PRISMS study will investigate an anti-inflammatory drug in individuals with REM sleep behavior disorder.

While “impressive,” the new study does not show that acetaminophen exposure causes reproductive organ changes, noted Dr. Hugh Taylor, a specialist in obstetrics and gynecology and reproductive endocrinology at Yale School of Medicine.